To determine the analgesic efficacy of CL-108 5 mg by comparison with placebo and the anti-emetic efficacy of CL-108 5 mg by comparison with hydrocodone 5 mg/acetaminophen 325 mg.
Adult patients with moderate or severe pain after bunionectomy will be randomized to CL-108 5 mg (hydrocodone 5 mg/acetaminophen 325 mg/ promethazine 12.5 mg), hydrocodone 5 mg/ acetaminophen 325 mg, or placebo under double-blind conditions. Over 48 hours they will use the assigned study medication and assess pain intensity, nausea, and vomiting. Uses of supplementary analgesic and antiemetic medications will be documented. Patient responses and adverse effects will also be documented during the 5-day outpatient period, too.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
349
hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg
hydrocodone 5 mg/APAP 325 mg
Placebo matching CL-108
Arizona Research Center
Phoenix, Arizona, United States
Chesapeake
Pasadena, Maryland, United States
Optimal Research
Austin, Texas, United States
Endeavor Clinical Research
San Antonio, Texas, United States
Percentage of Participants With OINV Over 48 Hours
Number and Percentage of participants With opioid-induced nausea and vomiting (OINV) who experienced any Vomiting / use of Anti-Emetic Medication Over 48 Hours
Time frame: Up to 48 hours
The Sum of Pain Intensity Differences (on PI-NRS) Over 48 Hours (SPID48)
The SPID48 endpoint is calculated from the PI-NRS values at baseline, every 30 minutes until hour 12, then every hour (when awake) until hour 48 as follows: * Each subsequent PI-NRS value is subtracted from the baseline PI-NRS value. * Each difference is weighted by the elapsed time from the previous PI-NRS value to the current one. * The weighed differences are summed to yield the SPID48. Summed pain intensity differences over 48 hours (SPID48) will be compared for patients treated with CL-108 5 mg and those treated with placebo. Pain intensity will be measured on a 0-10 Pain Intensity Numerical Rating Scale (PI-NRS), where 0 is "no pain" and 10 is "severe pain".
Time frame: Up to 48 hours
Percentage of Patients With Complete Absence of OINV (no Nausea, no Vomiting, and no Use of Anti-emetic Medication) Over 48 Hours
Percentage of patients with complete absence of OINV (no nausea, no vomiting, and no use of anti-emetic medication) over 48 hours comparing CL-108 5 mg to hydrocodone 5 mg/APAP 325 mg)
Time frame: Up to 48 hours
Percentage of Patients With Any Vomiting Over 48 Hours
Percentage of patients with any vomiting over 48 hours, comparing CL-108 5 mg to hydrocodone 5 mg/APAP 325 mg
Time frame: Up to 48 hours
Percentage of Patients With Any Nausea Over 48 Hours
Percentage of patients with any nausea over 48 hours, comparing CL-108 5 mg to hydrocodone 5 mg/APAP 325 mg
Time frame: Up to 48 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Jean Brown Research
Salt Lake City, Utah, United States
Percentage of Patients With Any Nausea or Vomiting Over 48 Hours
Percentage of patients with any nausea or vomiting over 48 hours, comparing CL-108 5 mg to hydrocodone 5 mg/APAP 325 mg
Time frame: Up to 48 hours
Percentage of Patients With Any Post-discharge Nausea and Vomiting (PDNV)
Percentage of patients with any Post-discharge Nausea and Vomiting (PDNV) over Days 3 to 7
Time frame: Day 3 to 7
Number of Doses of Study Medication Taken Over Days 3to7
Number of doses of study medication taken over Days 3 to 7
Time frame: Day3 to Day7
Number of Doses of Study Medication Taken Per Day Over Days 3to7
Number of doses of study medication taken per day over Days 3 to 7
Time frame: Day3 to Day7